Chen Shali, Khan Zia Ali, Cukiernik Mark, Chakrabarti Subrata
Department of Pathology, University of Western Ontario, London, Ontario N6A 5C1, Canada.
Am J Physiol Endocrinol Metab. 2003 Jun;284(6):E1089-97. doi: 10.1152/ajpendo.00540.2002. Epub 2003 Feb 11.
Increased extracellular matrix protein production leading to structural abnormalities is a characteristic feature of chronic diabetic complications. We previously showed that high glucose in endothelial cell culture leads to the upregulation of basement membrane protein fibronectin (FN) via an endothelin (ET)-dependent pathway involving activation of NF-kappaB and activating protein-1 (AP-1). To delineate the mechanisms of basement membrane thickening, we used an animal model of chronic diabetes and evaluated ET-dependent activation of NF-kappaB and AP-1 and subsequent upregulation of FN in three target organs of chronic diabetic complications. After 3 mo of diabetes, retina, renal cortex, and myocardium demonstrated increased FN mRNA and increased ET-1 mRNA expression. Increased FN expression was shown to be dependent on ET receptor-mediated signaling, as the increase was prevented by the dual ET receptor antagonist bosentan. NF-kappaB activation was most pronounced in the retina, followed by kidney and heart. AP-1 activation was also most pronounced in the retina but was similar in both kidney and heart. Bosentan treatment prevented NF-kappaB activation in the retina and heart and AP-1 activation in the retina and kidney. These data indicate that, although ETs are important in increased FN production due to diabetes, the mechanisms with respect to transcription factor activation may vary depending on the microenvironment of the organ.
细胞外基质蛋白生成增加导致结构异常是慢性糖尿病并发症的一个特征。我们之前表明,内皮细胞培养中的高糖通过涉及核因子κB(NF-κB)和激活蛋白-1(AP-1)激活的内皮素(ET)依赖性途径导致基底膜蛋白纤连蛋白(FN)上调。为了阐明基底膜增厚的机制,我们使用慢性糖尿病动物模型,评估慢性糖尿病并发症的三个靶器官中ET依赖性的NF-κB和AP-1激活以及随后FN的上调。糖尿病3个月后,视网膜、肾皮质和心肌显示FN mRNA增加以及ET-1 mRNA表达增加。FN表达增加显示依赖于ET受体介导的信号传导,因为双重ET受体拮抗剂波生坦可阻止这种增加。NF-κB激活在视网膜中最为明显,其次是肾脏和心脏。AP-1激活在视网膜中也最为明显,但在肾脏和心脏中相似。波生坦治疗可阻止视网膜和心脏中的NF-κB激活以及视网膜和肾脏中的AP-1激活。这些数据表明,尽管ETs在糖尿病导致的FN生成增加中很重要,但转录因子激活的机制可能因器官的微环境而异。